- Home
- PROK
PROK
ProKidney Corp.
as 07-26-2024 4:00pm EST
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | WINSTON-SALEM |
| Market Cap: | 326.5M | IPO Year: | N/A |
| Target Price: | $7.25 | AVG Volume (30 days): | 591.7K |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.57 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.12 - $13.51 | Next Earning Date: | 08-08-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of ProKidney Corp. (PROK)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Weber Darin J. | PROK | Chief Regulatory Officer | Jun 18 '24 | Sell | $2.82 | 17,238 | $48,616.33 | 120,718 | SEC Form 4 |
| Legorreta Pablo G. | PROK | Director10% Owner | Jun 13 '24 | Buy | $2.42 | 22,617,909 | $54,735,339.78 | 22,617,909 | SEC Form 4 |
| Control Empresarial de Capitales S.A. de C.V. | PROK | 10% Owner | Jun 11 '24 | Buy | $2.42 | 8,264,462 | $19,999,998.04 | 71,560,107 | SEC Form 4 |
| Weber Darin J. | PROK | Chief Regulatory Officer | May 20 '24 | Sell | $4.08 | 17,238 | $70,386.20 | 137,956 | SEC Form 4 |
| Weber Darin J. | PROK | SVP of Regulatory Development | Apr 18 '24 | Sell | $2.54 | 800 | $2,028.00 | 171,632 | SEC Form 4 |
| Weber Darin J. | PROK | SVP of Regulatory Development | Apr 18 '24 | Sell | $2.51 | 16,438 | $41,315.27 | 155,194 | SEC Form 4 |
| Weber Darin J. | PROK | SVP of Regulatory Development | Apr 16 '24 | Sell | $2.50 | 17,238 | $43,095.00 | 172,432 | SEC Form 4 |
| Weber Darin J. | PROK | SVP of Regulatory Development | Apr 1 '24 | Sell | $1.69 | 300 | $507.00 | 273,773 | SEC Form 4 |
| Weber Darin J. | PROK | SVP of Regulatory Development | Apr 1 '24 | Sell | $1.73 | 84,103 | $145,498.19 | 189,670 | SEC Form 4 |
| Control Empresarial de Capitales S.A. de C.V. | PROK | 10% Owner | Mar 13 '24 | Buy | $1.50 | 50,000 | $75,090.00 | 63,168,645 | SEC Form 4 |
| Control Empresarial de Capitales S.A. de C.V. | PROK | 10% Owner | Mar 13 '24 | Buy | $1.36 | 50,000 | $67,925.00 | 63,218,645 | SEC Form 4 |
| Control Empresarial de Capitales S.A. de C.V. | PROK | 10% Owner | Mar 13 '24 | Buy | $1.40 | 33,000 | $46,110.90 | 63,251,645 | SEC Form 4 |
| Control Empresarial de Capitales S.A. de C.V. | PROK | 10% Owner | Mar 13 '24 | Buy | $1.40 | 14,000 | $19,586.00 | 63,265,645 | SEC Form 4 |
| Control Empresarial de Capitales S.A. de C.V. | PROK | 10% Owner | Mar 13 '24 | Buy | $1.43 | 30,000 | $42,954.00 | 63,295,645 | SEC Form 4 |
| Palihapitiya Chamath | PROK | Nov 19 '23 | Sell | $1.31 | 5,183,367 | $6,785,027.40 | 0 | SEC Form 4 | |
| Palihapitiya Chamath | PROK | Nov 19 '23 | Sell | $1.31 | 2,073,000 | $2,713,557.00 | 0 | SEC Form 4 | |
| Palihapitiya Chamath | PROK | 10% Owner | Nov 15 '23 | Sell | $1.49 | 282,300 | $420,147.09 | 5,653,867 | SEC Form 4 |
| Palihapitiya Chamath | PROK | 10% Owner | Nov 15 '23 | Sell | $1.22 | 212,100 | $259,398.30 | 5,441,767 | SEC Form 4 |
| Palihapitiya Chamath | PROK | 10% Owner | Nov 15 '23 | Sell | $1.19 | 258,400 | $308,400.40 | 5,183,367 | SEC Form 4 |
| Palihapitiya Chamath | PROK | 10% Owner | Nov 6 '23 | Sell | $1.56 | 79,600 | $123,817.80 | 6,643,100 | SEC Form 4 |
| Palihapitiya Chamath | PROK | 10% Owner | Nov 6 '23 | Sell | $1.59 | 71,233 | $113,367.32 | 6,571,867 | SEC Form 4 |
| Palihapitiya Chamath | PROK | 10% Owner | Nov 6 '23 | Sell | $1.66 | 59,000 | $97,763.00 | 6,512,867 | SEC Form 4 |
| Palihapitiya Chamath | PROK | 10% Owner | Nov 1 '23 | Sell | $1.62 | 123,400 | $199,673.54 | 7,004,700 | SEC Form 4 |
| Palihapitiya Chamath | PROK | 10% Owner | Nov 1 '23 | Sell | $1.73 | 133,700 | $231,956.13 | 6,871,000 | SEC Form 4 |
| Palihapitiya Chamath | PROK | 10% Owner | Nov 1 '23 | Sell | $1.73 | 148,300 | $256,470.02 | 6,722,700 | SEC Form 4 |
Latest ProKidney Corp. News
PROK Breaking Stock News: Dive into PROK Ticker-Specific Updates for Smart Investing
MT Newswires
a month ago
ProKidney Closes Public, Registered Direct Offerings
GlobeNewswire
a month ago
ProKidney Announces the Closing of $140 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering, Including Exercise of Underwriters’ Option
MT Newswires
a month ago
ProKidney Prices Upsized $130 Million Stock Offering
GlobeNewswire
a month ago
ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
MT Newswires
a month ago
Sector Update: Health Care Stocks Mixed Premarket Tuesday
MT Newswires
2 months ago
ProKidney Launches $125 Million Stock Offering; Shares Fall After-Hours
GlobeNewswire
2 months ago
ProKidney Announces Proposed $125 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
MT Newswires
2 months ago
Sector Update: Health Care Stocks Decline Premarket Monday
Compare PROK vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PROK ProKidney Corp. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.